Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1.

Hensley, Patrick J; Seiler, Roland; Herr, Harry; Mouw, Kent W; Iyer, Gopa; Dyrskjøt, Lars; Nawroth, Roman; Goebell, Peter; Schmitz-Drager, Bernd; Todenhofer, Tilman; Black, Peter C; Kamat, Ashish M; Williams, Stephen B (2023). Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1. Urologic oncology - seminars and original investigations, 41(7), pp. 307-312. Elsevier 10.1016/j.urolonc.2023.01.001

[img] Text
1-s2.0-S1078143923000017-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (299kB)

The morbidity associated with radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) has fueled investigations into the feasibility of bladder preservation strategies after a favorable clinical response to neoadjuvant therapy (NAT). Identifying optimal candidates for bladder preservation is predicated on our ability to identify tumors with inherent cisplatin sensitivity and accurately stage patients before and after NAT. In the present review, we evaluate the accuracy and limitations of contemporary staging modalities and investigate clinical outcomes in patients with MIBC who were managed with bladder preservation after NAT. Lastly, we discuss the predictive role of cisplatin-sensitizing DNA damage response (DDR) gene alterations as a foundational component to current prospective clinical trials evaluating bladder preservation in the setting of MIBC.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Urologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Urologie

UniBE Contributor:

Seiler-Blarer, Roland

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1078-1439

Publisher:

Elsevier

Language:

English

Submitter:

Pubmed Import

Date Deposited:

30 Jan 2023 13:16

Last Modified:

17 Jun 2023 00:12

Publisher DOI:

10.1016/j.urolonc.2023.01.001

PubMed ID:

36702704

Uncontrolled Keywords:

Bladder cancer DNA damage response Genetic alteration Neoadjuvant therapy Predictors

BORIS DOI:

10.48350/177976

URI:

https://boris.unibe.ch/id/eprint/177976

Actions (login required)

Edit item Edit item
Provide Feedback